Regarding the prediction of response to chemoradiotherapy in rectal cancer by immunohistochemistry, Kuremsky et al. reported that the most commonly biomarkers evaluated were p53, EGFR, TYMS, Ki-67, p21, BCL-2, and BAX [48]. This evidence concerns the gene MKI67 and rectal cancer.